Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMOTE-P: Prediction of response to hormonal therapy in advanced and recurrent endometrial cancer
NL-OMON54286Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in endometrial cancer (EC) and uterine cancer, sponsored by Radboud University Medical Center. Primary endpoints: Response rate, Progression-free survival and 1 more. Started Oct 2022; status: recruiting.
02
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on NL-OMON54286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54286.